Related Experiment Video

Updated: Jun 12, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Glycemic control influences serum angiogenin concentrations in patients with type 2 diabetes

Janusz Siebert1, Magdalena Reiwer-Gostomska, Jolanta Mysliwska

  • 1Department of Family Medicine, University Centre for Cardiology, Medical University of Gdansk, Gdansk, Poland. jsiebert@gumed.edu.pl

Diabetes Care
|May 21, 2010
PubMed

Insights

Patients with poorly controlled type 2 diabetes exhibit lower serum angiogenin levels. This finding highlights a potential biomarker for diabetes management and associated vascular complications.

Area of Science:

  • Endocrinology
  • Cardiovascular Research
  • Biochemistry

Background:

  • Diabetes mellitus is a leading cause of microvascular and macrovascular complications.
  • Angiogenin is a protein involved in angiogenesis and tissue repair.
  • Understanding factors influencing angiogenin levels in diabetes is crucial for managing vascular health.

Purpose of the Study:

  • To investigate serum angiogenin levels in patients with type 2 diabetes.
  • To compare angiogenin levels between well-controlled and poorly controlled diabetic groups.

Main Methods:

  • A case-control study involving 49 diabetic patients and 40 non-diabetic controls.
  • Serum angiogenin levels were quantified using enzyme-linked immunosorbent assay (ELISA).
  • Diabetes control was assessed by HbA1c levels, with <7% defined as well-controlled.

Main Results:

  • Serum angiogenin levels were significantly lower in poorly controlled type 2 diabetes patients (HbA1c >7%) compared to well-controlled patients (P=0.001).
  • Poorly controlled diabetes was associated with longer disease duration, higher BMI, and elevated systolic blood pressure.
  • No significant differences in lipid profiles (total cholesterol, triglycerides, LDL, HDL) were observed between the groups.

Conclusions:

  • Poor glycemic control in type 2 diabetes is linked to reduced serum angiogenin levels.
  • Lower angiogenin may indicate impaired angiogenic potential in poorly controlled diabetes.
  • Angiogenin levels could serve as a potential biomarker for assessing diabetes control and vascular risk.
Abstract

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...